Anti-KIR2DL5.1 Antibody Products

Anti-KIR2DL5.1 antibodies enable researchers to detect and measure the KIR2DL5.1 antigen in biological samples. This target is a reported synonym of the KIR2DL5A gene, which encodes killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 5A. This protein is a known receptor on natural killer (NK) cells for HLA-C alleles. The human version of KIR2DL5.1 has a canonical amino acid length of 375 residues and a protein mass of 40.7 kilodaltons. It is reported to be localized in the cell membrane of cells. KIR2DL5.1 is a member of the Immunoglobulin protein superfamily.

Your search terms and filters produced no results.

Please use the Antibodies search tool above to find what you're looking for.

Write a Review

Recombinant REAfinity™ Antibodies
Recombinant REAfinity™ Antibodies for reproducible flow cytometry results Recombinant antibodies are the next generation of engineered flow cytometry antibodies, and represent the first truly fundamental shift in antibodies since monoclonals were first developed 40 years ago. Recombinant antibodies are derived from a defined set of genes, and the production process is highly standardized. Therefore, these antibodies are consistent in their structure and performance, leading to high experimental...
Anti-Iba-1 Polyclonal Antibody, Unconjugated
Anti Iba-1 is specifically reactive to microglia and macrophages, and are appropriate for immuno-double staining of brain tissues and cell culture in combination with monoclonal antibody to GFAP, which specifically reactes to astrocytes.

More Suggested Products »

CD33 Antibody From BD Biosciences Does Not Work as Expected

CD33 is typically positive on monocytes (bright) and neutrophils (intermediate/dim) but completely negative on lymphocytes. We extensively use this antibody as one of the markers for acute myeloid leukemia specimens.
Highly Recommended Anti-Mouse CD19 Monoclonal Antibody for Primary Cells

We perform in vivo/in vitro targeting and engineering of mouse B cells. To analyze the on and off-target efficiency, we analyze different immune subsets. After initial gating on CD45+ cells, this CD19 antibody is used to gate on CD19+ B-cell population.

More Recent Product Reviews »